SHIM
TBPH icon

Stone House Investment Management’s Theravance Biopharma TBPH Stock Holding History

Stone House Investment Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.33K Buy
255
+15
+6% +$248 ﹤0.01% 585
2026
Q1 		$3.9K Buy
+240
New +$4.25K ﹤0.01% 493

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Stone House Investment Management's TBPH Position: Q2 2026 in Review

Stone House Investment Management increased its Theravance Biopharma (TBPH) stake by 6.3% in Q2 2026, buying an estimated $248 and bringing the position to 255 shares worth $4.33K. The position accounts for ﹤0.01% of the portfolio, ranked #585.

Stone House Investment Management first reported a position in TBPH in Q1 2026 and has held it in 2 quarters since. 179 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Stone House Investment Management held 255 shares of Theravance Biopharma worth $4.33K as of Q2 2026.
  • Stone House Investment Management bought 15 Theravance Biopharma shares in Q2 2026, an estimated $248.
  • Theravance Biopharma made up ﹤0.01% of Stone House Investment Management's portfolio in Q2 2026, its #585 holding.
  • Stone House Investment Management first reported a position in Theravance Biopharma in Q1 2026 and has held it in 2 quarters since.
  • 179 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Stone House Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.